Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 19/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 19/20 | 1.00 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199602 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2PTGER1PTGER4PTGER3 | |
| SCHEMBL9199596 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2PTGER1PTGER4PTGER3 | |
| SCHEMBL9202454 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL9202461 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL9202469 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL9202560 | 0.83 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL9202568 | 0.83 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL9202577 | 0.83 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL9204592 | 0.82 | LTB4R (0.69) | LTB4RLTB4R2PTGER1PTGER4PTGER3 | |
| SCHEMBL9204585 | 0.82 | LTB4R (0.69) | LTB4RLTB4R2PTGER1PTGER4PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0538416-B1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1995-08-09 | — | — | EP | claimed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | claimed |
| US-5232948-A | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-08-03 | — | — | US | claimed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | claimed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-0538416-B1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0538416-A4 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1994-05-18 | — | — | EP | disclosed |
| US-5232948-A | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0538416-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992004315-A1 | SUBSTITUTED MONOCYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | LTB4R 1737/4885LTB4R2 1873/4885PTGER1 1161/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | LTB4R 2160/4885LTB4R2 2448/4885PTGER1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.